Astellas Pharma US, Inc.
Northbrook
Illinois
60062
United States
746 articles about Astellas Pharma US, Inc.
-
Outcome Capital Announces Acquisition of Propella Therapeutics, Portfolio Company of Peterson Companies, by Astellas Pharma
1/4/2024
Outcome Capital, a highly specialized life sciences advisory and investment banking firm, announced that Propella Therapeutics, a biopharmaceutical company that has developed a platform for lymphatic targeting to create best- or first-in-class oncology drugs, has been acquired by Astellas Pharma.
-
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
12/28/2023
Elpiscience Biopharma, Ltd. and Astellas Pharma Inc. announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program.
-
Astellas Completes Acquisition of Propella Therapeutics
12/21/2023
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today that it has completed the acquisition of Propella Therapeutics, Inc. (President and CEO: William Moore, "Propella"), and has become a wholly owned subsidiary of Astellas as of U.S. Eastern Time December 21, 2023.
-
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
12/17/2023
Astellas Pharma Inc. contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium.
-
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
12/15/2023
Astellas Pharma Inc. and Pfizer Inc. announced that on December 15, 2023 the U.S. Food and Drug Administration has approved PADCEV® with KEYTRUDA® for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
-
Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics
12/13/2023
Astellas Venture Management LLC, a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission BioCapital BioLabs, a life-science incubator, announced TippingPoint Biosciences and Altay Therapeutics as the winners of the Astellas-sponsored "Future Innovator Prize" at MBC BioLabs.
-
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause
12/10/2023
Astellas Pharma Inc. announced the European Commission on December 7 approved VEOZATM 45 mg once daily for the treatment of moderate to severe vasomotor symptoms associated with menopause.
-
FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
12/8/2023
Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved CRESEMBA® (isavuconazonium sulfate), an azole antifungal drug, for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients.
-
The company is hoping the topline results for Veozah, which won FDA approval in May, will support health technology assessments for reimbursement negotiations in Europe.
-
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
11/29/2023
Astellas Pharma Inc. will present 24-week results from the Phase 3b DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant in an oral presentation on November 30 at the 15th Congress of the European Society of Gynecology in Amsterdam, The Netherlands.
-
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
11/17/2023
Astellas Pharma Inc. and Pfizer Inc. announced that the companies received an approval by the U.S. Food and Drug Administration of a supplemental New Drug Application for XTANDI®, following FDA expedited development and review programs, based on results from the Phase 3 EMBARK trial.
-
Xtandi is now approved to treat nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis with or without a gonadotropin-releasing hormone analog therapy.
-
University of Tsukuba and Astellas Confirm a Strategic Partnership
11/16/2023
University of Tsukuba and Astellas Pharma Inc. announced that they have signed a letter of confirmation regarding a strategic partnership to accelerate the digitalization of the drug discovery research field, as well as the development of the life science ecosystem in Tsukuba and Kashiwa-no-ha, and to further accelerate innovative drug discovery research and development.
-
The Japanese pharma contends that an analysis of the four deaths in its AT132 gene therapy clinical trial shows it is still viable as a potential treatment for a fatal, rare genetic disease.
-
Astellas to Acquire Propella Therapeutics
11/15/2023
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Propella Therapeutics, Inc. (President and CEO: William Moore, "Propella") today announced that Astellas, through a U.S. subsidiary, and Propella have entered into a merger agreement pursuant to which Astellas will acquire Propella.
-
Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology
11/15/2023
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that The Lancet Neurology published a preliminary data analysis from the ASPIRO trial, evaluating the safety and efficacy of investigational AT132 (resamirigene bilparvovec), an adeno-associated viral vector (AAV) gene replacement therapy designed to deliver a functional human MTM1 gene for the treatment of pediatric patients with X-linked myotubular myopathy (XLMTM).
-
IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years
11/4/2023
Astellas Pharma Inc. announced results from the GATHER2 Phase 3 clinical trial, demonstrating IZERVAY™ continued to reduce the rate of geographic atrophy lesion growth for both every month and every-other-month dosing vs. sham through 2 years of treatment in patients with GA secondary to age-related macular degeneration.
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
10/22/2023
Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus Padcev, an antibody-drug conjugate, compared to chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
-
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
10/22/2023
Astellas Pharma Inc. and Seagen Inc. announced results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy.
-
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
10/15/2023
Astellas Pharma Inc. will share new research results during the European Society for Medical Oncology Congress 2023 from October 20-24, showcasing the company's focus on making a meaningful difference for people living with hard-to-treat cancers.